Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tankyrase 1 (TNKS1) and Tankyrase 2 (TNKS2), also known as PARP5a and PARP5b, are enzymes belonging to the poly(ADP-ribose) polymerase family that catalyze the transfer of ADP-ribose units onto target proteins (UniProt O95271, Q9H2K2). They play a critical role in the canonical Wnt/beta-catenin signaling pathway by PARsylating AXIN, a scaffold protein in the beta-catenin destruction complex, leading to its ubiquitination and proteasomal degradation (PubMed: 19759582). This process facilitates the stabilization and nuclear translocation of beta-catenin, driving the expression of genes involved in cell proliferation and survival. Additionally, tankyrases regulate telomere length by PARsylating TRF1, releasing it from telomeric DNA to allow access for telomerase (PubMed: 9843510). Due to their role in promoting oncogenic Wnt signaling, tankyrases are major therapeutic targets in cancers such as colorectal, breast, and lung cancer (PubMed: 32824158). Small-molecule inhibitors targeting the catalytic PARP domain of TNKS1/2 have shown efficacy in preclinical models, though clinical progression is often hindered by gastrointestinal toxicity due to the essential role of Wnt signaling in intestinal stem cell maintenance (PubMed: 27535974).
Inhibition of the catalytic PARP domain to prevent the PARsylation of substrate proteins such as AXIN, which stabilizes the beta-catenin destruction complex and leads to the degradation of beta-catenin.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tankyrase 1 (TNKS1) and Tankyrase 2 (TNKS2) (TNKS1/2).